Treatment of Calcinosis Cutis Associated with Autoimmune Connective Tissue Diseases

Overview

Journal Arch Dermatol Res

Specialty Dermatology

Date 2024 Jun 15

PMID 38878086

Authors

Charles B Lau

Gideon P Smith

Affiliations

Soon will be listed here.

Abstract

Calcinosis cutis is a condition that is commonly associated with autoimmune connective tissue diseases. It is characterized by the deposition of insoluble calcium salts in the skin and subcutaneous tissue, which can cause pain, impair function, and have significant impacts on quality of life. Calcinosis cutis is difficult to manage because there is no generally accepted treatment: evidence supporting treatments is mostly comprised of case reports and case series, sometimes yielding mixed findings. Both pharmacologic and procedural interventions have been proposed to improve calcinosis cutis, and each may be suited to different clinical scenarios. This review summarizes current treatment options for calcinosis cutis, with discussion of recommendations based on patient-specific factors and disease severity.

Citing Articles

Treatment of Calcinosis in Dermatomyositis-Case Report and Review.

Fraczek A, Kuna J, Rybak dObyrn J, Krajewska-Wlodarczyk M, Owczarczyk-Saczonek A J Clin Med. 2024; 13(20).

PMID: 39458184 PMC: 11508430. DOI: 10.3390/jcm13206234.

References

Dima A, Balanescu P, Baicus C . Pharmacological treatment in calcinosis cutis associated with connective-tissue diseases. Rom J Intern Med. 2014; 52(2):55-67. View

Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E . Calcinosis cutis: part I. Diagnostic pathway. J Am Acad Dermatol. 2011; 65(1):1-12. DOI: 10.1016/j.jaad.2010.08.038. View

Boulman N, Slobodin G, Rozenbaum M, Rosner I . Calcinosis in rheumatic diseases. Semin Arthritis Rheum. 2005; 34(6):805-12. DOI: 10.1016/j.semarthrit.2005.01.016. View

Goel S, Bellovich K, McCullough P . Treatment of severe metastatic calcification and calciphylaxis in dialysis patients. Int J Nephrol. 2011; 2011:701603. PMC: 3056381. DOI: 10.4061/2011/701603. View

Edsall L, English 3rd J, Teague M, Patterson J . Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol. 2004; 31(3):247-53. DOI: 10.1111/j.0303-6987.2004.00169.x. View

Fisler R, Liang M, Fuhlbrigge R, Yalcindag A, Sundel R . Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002; 47(4):505-11. DOI: 10.1067/mjd.2002.122196. View

Valenzuela A, Chung L . Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?. J Scleroderma Relat Disord. 2022; 7(1):7-23. PMC: 8922676. DOI: 10.1177/23971983211053245. View

Balin S, Wetter D, Andersen L, Davis M . Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009. Arch Dermatol. 2011; 148(4):455-62. DOI: 10.1001/archdermatol.2011.2052. View

Valenzuela A, Baron M, Rodriguez-Reyna T, Proudman S, Khanna D, Young A . Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. Semin Arthritis Rheum. 2020; 50(5):891-896. PMC: 8205269. DOI: 10.1016/j.semarthrit.2020.06.007. View

10.

Dalakas M, Illa I, Dambrosia J, Soueidan S, Stein D, Otero C . A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993; 329(27):1993-2000. DOI: 10.1056/NEJM199312303292704. View

11.

Ballow M . Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer. 1991; 68(6 Suppl):1430-6. DOI: 10.1002/1097-0142(19910915)68:6+<1430::aid-cncr2820681405>3.0.co;2-4. View

12.

Schanz S, Ulmer A, Fierlbeck G . Response of dystrophic calcification to intravenous immunoglobulin. Arch Dermatol. 2008; 144(5):585-7. DOI: 10.1001/archderm.144.5.585. View

13.

Penate Y, Guillermo N, Melwani P, Martel R, Hernandez-Machin B, Borrego L . Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin. J Am Acad Dermatol. 2009; 60(6):1076-7. DOI: 10.1016/j.jaad.2008.09.051. View

14.

Galimberti F, Li Y, Fernandez A . Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis. J Am Acad Dermatol. 2015; 73(1):174-6. DOI: 10.1016/j.jaad.2015.03.047. View

15.

Kalajian A, Perryman J, Callen J . Intravenous immunoglobulin therapy for dystrophic calcinosis cutis: unreliable in our hands. Arch Dermatol. 2009; 145(3):334. DOI: 10.1001/archdermatol.2008.620. View

16.

de Paula D, Klem F, Lorencetti P, Muller C, Azevedo V . Rituximab-induced regression of CREST-related calcinosis. Clin Rheumatol. 2012; 32(2):281-3. DOI: 10.1007/s10067-012-2124-z. View

17.

Daoussis D, Antonopoulos I, Liossis S, Yiannopoulos G, Andonopoulos A . Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum. 2012; 41(6):822-9. DOI: 10.1016/j.semarthrit.2011.11.007. View

18.

Narvaez J, Pirola J, LLuch J, Juarez P, Nolla J, Valenzuela A . Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature. Autoimmun Rev. 2019; 18(3):262-269. DOI: 10.1016/j.autrev.2018.10.006. View

19.

Kasi P, Tawbi H, Oddis C, Kulkarni H . Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care. 2012; 16(4):231. PMC: 3580676. DOI: 10.1186/cc11304. View

20.

Hoeltzel M, Oberle E, Robinson A, Agarwal A, Rider L . The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep. 2014; 16(12):467. PMC: 5118224. DOI: 10.1007/s11926-014-0467-y. View